Eugia – Recall of acyclovir injection

- On September 27, 2022, Eugia announced a voluntary recall of one lot of acyclovir sodium injection to the consumer level due to a product complaint for the presence of a dark red, brown and black particulate inside the vial.

    — Clinical Services did not identify any impacted members thus notifications will not be sent.
    — Other acyclovir injection products made by Eugia are available for use.

- The recalled lot was distributed June 8, 2022, through June 13, 2022.

Product Description	NDC#	Lot# (Expiration Date)
Acyclovir sodium injection 500 mg per 10 mL (50 mg/mL), 10 mL single dose vial	55150-154-10	AC22006 (8/2023)

- The administration of an intravenous product containing particulates has the potential to result in inflammation, allergic reactions, or circulatory system complications which could be life-threatening.

- Acyclovir injection is indicated for the treatment of herpes simplex infections in immunocompromised patients, initial episodes of herpes genitalis, herpes simplex encephalitis, neonatal herpes infections, and varicella-zoster infections in immunocompromised patients.

- To date, Eugia has not received reports of any adverse events or identifiable safety concerns attributed to the product consumed for this recalled lot.

- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately. Contact Qualanex by phone at **1-888-280-2046** or email **recall@qualanex.com** for return information.

- Patients should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled products.

- Anyone with questions may contact the Eugia Drug Safety Department by phone at **1-866-850-2876** or email **pvg@aurobindousa.com** for more information.